Oncocyte to Participate at Upcoming Investor Conferences
Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics firm, announced participation in key conferences aimed at enhancing patient outcomes.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics firm, announced participation in key conferences aimed at enhancing patient outcomes. Management will present at the UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2022, and participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 15, 2022. Oncocyte focuses on proprietary tests like DetermaRx™ for lung cancer recurrence and DetermaIO™ for immunotherapy response prediction. Their goal is to improve cancer diagnosis and care through personalized insights.
Details
News Market Reaction – OCX
The recorded move for OCX in the trading session of this news was +13.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that its management team will participate at the following conferences:
- UBS Genomics 2.0 and MedTech Innovations Summit
Presenting on Thursday, August 11, 2022 at 5:00 p.m. Eastern Time in Dana Point, California. The live audio webcast and replay of the presentation may be accessed for 180 days on the “Investors” section of the company’s website at https://oncocyte.com/.
- 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference
Participating on Monday, August 15, 2022
About Oncocyte
Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.
Through its proprietary tests and pharmaceutical services business, the Company aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients at every stage. DetermaRx™ identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The Company’s pipeline of tests in development also includes DetermaTx™, which will assess mutational status of a tumor, DetermaCNI™, a blood-based monitoring test, DetermaMx™, a long-term recurrence monitoring test, and VitaGraft™, a blood-based solid organ transplantation monitoring test. In addition, Oncocyte’s pharmaceutical services provide companies that are developing new cancer treatments a full suite of molecular testing services to support the drug development process.
DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™, DetermaMx™ and VitaGraft™ are trademarks of Oncocyte Corporation.
Investor Contact
Caroline Corner
ICR Westwicke
(415) 202-5678
caroline.corner@westwicke.com
Media Contact
Megan Kernan
ICR Westwicke Healthcare PR
Tel: 646.677.1870
Megan.kernan@westwicke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.